FMP

FMP

Enter

JSPR - Jasper Therapeutics,...

Financial Summary of Jasper Therapeutics, Inc.(JSPR), Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for h

photo-url-https://financialmodelingprep.com/image-stock/JSPR.png

Jasper Therapeutics, Inc.

JSPR

NASDAQ

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.

21.18 USD

-0.85 (-4.01%)

About

ceo

Mr. Ronald A. Martell

sector

Healthcare

industry

Biotechnology

website

https://jaspertherapeutics.com

exchange

NASDAQ

Description

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is ...

CIK

0001788028

ISIN

US4718712023

CUSIP

471871103

Address

2200 Bridge Pkwy

Phone

650 549 1400

Country

US

Employee

45

IPO Date

Jan 10, 2020

Summary

CIK

0001788028

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

471871103

ISIN

US4718712023

Country

US

Price

21.18

Beta

2.22

Volume Avg.

115.55k

Market Cap

319.51M

Shares

-

52-Week

4.0-31.01

DCF

8.06

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.34

P/B

-

Website

https://jaspertherapeutics.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest JSPR News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep